company background image
KNE logo

Kane Biotech TSXV:KNE Stock Report

Last Price

CA$0.10

Market Cap

CA$13.2m

7D

-9.1%

1Y

-16.7%

Updated

24 Feb, 2024

Data

Company Financials

KNE Stock Overview

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.

KNE fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Kane Biotech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kane Biotech
Historical stock prices
Current Share PriceCA$0.10
52 Week HighCA$0.14
52 Week LowCA$0.05
Beta0.55
1 Month Change17.65%
3 Month Change53.85%
1 Year Change-16.67%
3 Year Change-25.93%
5 Year Change17.65%
Change since IPO-94.29%

Recent News & Updates

Recent updates

Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Nov 05
Here's Why Kane Biotech (CVE:KNE) Can Afford Some Debt

Is Kane Biotech (CVE:KNE) A Risky Investment?

Jul 14
Is Kane Biotech (CVE:KNE) A Risky Investment?

Is Kane Biotech (CVE:KNE) A Risky Investment?

Mar 27
Is Kane Biotech (CVE:KNE) A Risky Investment?

Shareholder Returns

KNECA BiotechsCA Market
7D-9.1%1.4%1.0%
1Y-16.7%-23.4%3.6%

Return vs Industry: KNE exceeded the Canadian Biotechs industry which returned -25% over the past year.

Return vs Market: KNE underperformed the Canadian Market which returned 3.3% over the past year.

Price Volatility

Is KNE's price volatile compared to industry and market?
KNE volatility
KNE Average Weekly Movement16.9%
Biotechs Industry Average Movement13.1%
Market Average Movement8.6%
10% most volatile stocks in CA Market17.6%
10% least volatile stocks in CA Market3.2%

Stable Share Price: KNE's share price has been volatile over the past 3 months.

Volatility Over Time: KNE's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
2001n/aMarc Edwardshttps://kanebiotech.com

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names.

Kane Biotech Inc. Fundamentals Summary

How do Kane Biotech's earnings and revenue compare to its market cap?
KNE fundamental statistics
Market capCA$13.18m
Earnings (TTM)-CA$4.32m
Revenue (TTM)CA$2.74m

4.8x

P/S Ratio

-3.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KNE income statement (TTM)
RevenueCA$2.74m
Cost of RevenueCA$1.43m
Gross ProfitCA$1.31m
Other ExpensesCA$5.63m
Earnings-CA$4.32m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.033
Gross Margin47.79%
Net Profit Margin-157.48%
Debt/Equity Ratio-116.8%

How did KNE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.